[Ad hoc announcement pursuant to Art. 53 LR] Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer
The SKYSCRAPER-01 study evaluatingtiragolumab plusTecentriq did not meet its co-primary endpoint of progression-free survivalThe other co-primary endpoint of overall survival was immature and the study will continue until the next planned analysisThetiragolumab developmentprogramme continues as planned in non-small cell lung cancer and other cancer typesBasel, 11 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from its phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq ® (atezolizumab) versus Tecentriq alone as an initial (first-line) tre...
Source: Roche Media News - May 11, 2022 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer
The SKYSCRAPER-01 study evaluatingtiragolumab plusTecentriq did not meet its co-primary endpoint of progression-free survivalThe other co-primary endpoint of overall survival was immature and the study will continue until the next planned analysisThetiragolumab developmentprogramme continues as planned in non-small cell lung cancer and other cancer typesBasel, 11 May 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from its phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq ® (atezolizumab) versus Tecentriq alone as an initial (first-line) tre...
Source: Roche Investor Update - May 11, 2022 Category: Pharmaceuticals Source Type: news

What is in the Differential Diagnosis for Green, Blue or Violet Skin Conditions?
Discussion Acrocyanosis is commonly seen in the newborn period as the baby transitions to extra-uterine life. It appears as blue-purple coloration of the distal extremities which usually improves over several hours. Blue melanocytosis is also a common normal variant of skin color. It usually is seen on the posterior surface of the body around the spine and buttocks, but can also be on the upper parts of the extremities. It is a blue-black coloration that shows a normal skin undertone when palpated. This is the second in a short case series of differential diagnoses of colored skin conditions. An introduction to dermatologi...
Source: PediatricEducation.org - May 2, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Liquid Biopsy in HCC: Valuable Tool for Detection, Monitoring Liquid Biopsy in HCC: Valuable Tool for Detection, Monitoring
Further research is needed, though, to overcome barriers to the routine clinical use of liquid biopsy for patients with hepatocellular carcinoma (HCC).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 29, 2022 Category: Cancer & Oncology Tags: Gastroenterology News Source Type: news

Incidence of HCV Related HCC in the Era of IFN-free Therapies Incidence of HCV Related HCC in the Era of IFN-free Therapies
This study examined trends over time of HCV-associated hepatocellular carcinoma. How has incidence changed since the introduction of IFN-free therapies?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 25, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

What is in the Differential Diagnosis for Red, Orange or Yellow Skin Conditions?
Discussion This is the first in a short case series of differential diagnoses of colored skin conditions. A differential diagnosis by distribution and common pattern can be found here. For green, blue and violet conditions, a review can be found here. For black and white conditions, a review can be found here. For brown and grey conditions, a review can be found here. Note that any color can be a normal variant for an individual or is physiologic for a given state. The skin is the largest organ of the body. It can be easily examined but for many clinicians continues to be difficult to describe what they are seeing. Analo...
Source: PediatricEducation.org - April 25, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

CHMP recommends EU approval of Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resectable Stage II-III NSCLC compared with best supportive careMore than half of people with early-stage NSCLC experience disease recurrence following surgery,1 and most of these recurrent tumours are metastatic, making them incurable2-7If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeBasel, 22 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Commi...
Source: Roche Media News - April 22, 2022 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Tecentriq as adjuvant treatment for a subset of people with early-stage non-small cell lung cancer
In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resectable Stage II-III NSCLC compared with best supportive careMore than half of people with early-stage NSCLC experience disease recurrence following surgery,1 and most of these recurrent tumours are metastatic, making them incurable2-7If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in EuropeBasel, 22 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Commi...
Source: Roche Investor Update - April 22, 2022 Category: Pharmaceuticals Source Type: news

Ad hoc announcement pursuant to Art. 53 LR Roche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer
Ad hoc announcement pursuant to Art.53 LRRoche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancerSKYSCRAPER-02, the firstrandomized study oftiragolumab in extensive stage small-cell lung cancer (ES-SCLC),did not meet its co-primary endpoint of progression-free survivalES-SCLC is a hard-to-treat disease andTecentriq plus chemotherapy remains a standard of careTiragolumab continues to be evaluated in non-small cell lung cancer (NSCLC) and other cancer types through additional phase III trials as plannedBasel, 30 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the p...
Source: Roche Media News - March 30, 2022 Category: Pharmaceuticals Source Type: news

Ad hoc announcement pursuant to Art. 53 LR Roche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancer
Ad hoc announcement pursuant to Art.53 LRRoche provides update on phase III SKYSCRAPER-02 study in extensive-stage small cell lung cancerSKYSCRAPER-02, the firstrandomized study oftiragolumab in extensive stage small-cell lung cancer (ES-SCLC),did not meet its co-primary endpoint of progression-free survivalES-SCLC is a hard-to-treat disease andTecentriq plus chemotherapy remains a standard of careTiragolumab continues to be evaluated in non-small cell lung cancer (NSCLC) and other cancer types through additional phase III trials as plannedBasel, 30 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the p...
Source: Roche Investor Update - March 30, 2022 Category: Pharmaceuticals Source Type: news

Glycosylated 4-methylumbelliferone as Targeted Therapy for HCC Glycosylated 4-methylumbelliferone as Targeted Therapy for HCC
This study found that glycosylation of 4MUR can improve its selectivity to tumor cells and may potentially be an effective targeted therapy for hepatocellular carcinoma.Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 28, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Immunotherapy Treatment Shows Promise for Resectable Liver Cancer Immunotherapy Treatment Shows Promise for Resectable Liver Cancer
Perioperative immunotherapy appears to be safe in the setting of resectable hepatocellular carcinoma, according to findings from an open-label phase 2 clinical trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 25, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Revised Immunogenomic Classification of Liver Cancer May Help Predict Immunotherapy Response Revised Immunogenomic Classification of Liver Cancer May Help Predict Immunotherapy Response
A revised immunogenomic classification for hepatocellular carcinoma includes several novel mechanisms of immune response and evasion and may help to better gauge outcome associated with immunotherapy, the developers say.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 14, 2022 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

Hepatocellular Carcinoma in Noncirrhotic and Cirrhotic livers Hepatocellular Carcinoma in Noncirrhotic and Cirrhotic livers
What are the clinicopathologic differences between hepatocellular carcinoma arising in noncirrhotic and cirrhotic livers?American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 9, 2022 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Drug Combo Ups Ulcer Risk After Cryoablation in Patients With HCC Drug Combo Ups Ulcer Risk After Cryoablation in Patients With HCC
Patients with hepatocellular carcinoma should be switched from a PD-1, TKI combination to monotherapy after cryoablation. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 7, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news